2 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Oryzon Genomics S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iadademstat + SBRT With Atezo in ES-SCLC Iadademstat, Atezolizumab, SBRT - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Recruiting | Yale University | 15 | 2026-01-20 | 2026-09-14 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Iadademstat, Gilteritinib Oral Tablet - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Active not recruiting | Oryzon Genomics S.A. | 50 | 2022-11-14 | 2026-08-24 |
| Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population vafidemstat, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Oryzon Genomics S.A. | 211 | 2021-03-26 | 2026-05-05 |
| Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease ORY-2001 Low dose, ORY-2001 High dose, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Completed | Oryzon Genomics S.A. | 24 | 2019-05-16 | 2021-03-05 |
Leukemia, Myeloid, Acute (2) · Alzheimer Disease (1) · Borderline Personality Disorder (1) · Carcinoma, Neuroendocrine (1) · GATA2 Deficiency (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
iadademstat (4) · vafidemstat (2) · Azacitidine (1) · Biopsy (1) · Paclitaxel (1) · Specimen Handling (1) · atezolizumab (1) · gilteritinib (1) · venetoclax (1)
United States (6) · Bulgaria (1) · Germany (1) · Serbia (1) · Spain (1)
Michael Ropacki, MD (2) · Annie Chiang, MD (1) · Curtis A Lachowiez (1) · Namrata Vijavergia (1)